在丹麦,在抗瘤药物治疗中实施快速药物脱敏,使用单袋协议
Trine Holm Rasmussen1, Charlotte Gotthard Mortz1, Per Pfeiffer2
1Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis (ORCA), Odense University Hospital, Odense, Denmark.
Clinical and translational allergy
|August 14, 2025
概括
快速药物脱敏 (RDD) 和药物诱导测试 (DPT) 能够使癌症患者能够继续接受必要的抗瘤治疗,尽管有即时的过敏反应. 这项北欧计划表现出高的成功率和可管理的突破性反应.
科学领域:
- 过敏和免疫学 过敏和免疫学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 对抗瘤药物的即时药物过敏反应 (IDHR) 对癌症治疗构成了挑战.
- 快速药物脱敏 (RDD) 和药物挑测试 (DPT) 是南欧和美国的既定管理策略.
- 北欧缺乏针对IDHR癌症患者的综合性过敏治疗计划.
研究的目的:
- 报告北欧首个包含RDD和DPT用于癌症患者的过敏治疗计划的结果.
- 评估RDD程序的成功率,突破反应 (BTR) 和治疗持续时间.
主要方法:
- 一项前性观察性研究包括IDHR患者对抗瘤药物的治疗.
- 患者接受了DPT,以确定安全的替代品或排除过敏症.
- 使用单袋协议进行RDD,并仔细记录结果和BTR.
主要成果:
- 在28个月的时间里,包括72名患者;DPT确定了5种药物的替代品,并排除了6种药物的过敏性.
- 在60名患者中进行了RDD,248项手术中有247项成功完成.
- 53%的患者 (27%的手术) 出现突破性反应,大多为轻度至中度; 96%的RDD在6小时以下完成.
结论:
- 实施的过敏治疗计划有效地使得IDHR的癌症患者能够继续接受抗瘤治疗.
- 使用DPT和标准化的一袋RDD协议证明是成功和安全的.
- 该计划代表了在北欧癌症治疗中管理药物过敏症的关键进展.
相关概念视频
Desensitization and Tachyphylaxis
2.2K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
2.2K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
259
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
259
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
322
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
322
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
443
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
443


